ICYMI: Top Highlights From ACC 2022

The American College of Cardiology’s 71st Scientific Session was held on April 2-4, 2022, in Washington, DC, with a program that covered how to address the impact of social determinants of health on cardiovascular outcomes, understanding the latest developments in digital health, and the role of COVID-19 on heart health.

Here are the key takeaways from the meeting.

New HF Definition, Stage Updates Outlined in 2022 ACC/AHA/HFSA Guidelines

A panel of experts highlighted updates to the 2022 American Heart Association (AHA)/ACC/Heart Failure Society of America (HFSA) guidelines. New additions included better management that incorporated social determinants of health and a new definition for heart failure.

Dr Raul Santos Explains the Benefits of Treating Children With FH Early

Raul Santos, MD, PhD, director, Lipid Clinic at the Heart Institute, and associate professor, University of São Paulo Medical School, Brazil, spoke on the benefits and risks of early treatment for children with familial hypercholesterolemia (FH).

SCORED: Sotagliflozin Leads to Reductions in CV Death, MI, Stroke Regardless of CVD Presence

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular (CV) programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, presented updated findings from the SCORED trial that further highlight the benefits of sotagliflozin among patients with type 2 diabetes and chronic kidney disease.

Consider the Whole Patient When Choosing Treatment, Says Dr Marc Bonaca

“We have to treat our patients, not disease states,” said Marc Bonaca, MD, MPH, CPC of Clinical Research, CPC of Community Health, University of Colorado School of Medicine, in an interview on holistic approaches and rivaroxaban treatment.